MDBIF (TrivarX) Dividend-Payout-to-FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is TrivarX Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.

TrivarX Business Description

Other Exchanges TRI:Australia
Address 647 Beaufort Street, Mount Lawley, WA, AUS, 6050
TrivarX Ltd is an Australian health technology company focused on the development of artificial intelligence-driven devices for the screening and diagnosis of behavioral health conditions, particularly depression and other mental health disorders. The company's technology is based on proprietary algorithms that analyze sleep architecture and heart rate variability data, collected through wearable and non-invasive monitoring devices, to identify physiological biomarkers associated with mental health conditions. TrivarX operates through a single business segment encompassing the research, development, and commercialization of its software-as-a-service product. Its primary markets are Australia and the United States, where it targets healthcare providers, clinicians, and health systems seeking objective, data-driven tools for behavioral health screening. The company generates revenue through the licensing and delivery of its software platform and related diagnostic services.